Research Analysts Offer Predictions for Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR) – Equities researchers at Zacks Research increased their Q1 2025 earnings estimates for Cencora in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $3.42 per share for the quarter, up from their prior forecast of $3.28. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Zacks Research also issued estimates for Cencora’s Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.82 EPS, Q3 2026 earnings at $3.85 EPS, Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $16.17 EPS and FY2027 earnings at $17.41 EPS.

Several other research firms have also recently weighed in on COR. Bank of America reissued a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners reduced their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Robert W. Baird increased their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Cencora Trading Up 0.7 %

Shares of COR stock opened at $251.55 on Monday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora has a 12-month low of $195.83 and a 12-month high of $253.27. The stock has a market capitalization of $49.57 billion, a P/E ratio of 33.50, a P/E/G ratio of 1.67 and a beta of 0.44. The firm’s 50 day moving average is $234.91 and its 200 day moving average is $232.61.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s dividend payout ratio is 29.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 93,018 shares of company stock valued at $22,478,942 over the last three months. Corporate insiders own 15.80% of the company’s stock.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. New Millennium Group LLC purchased a new stake in Cencora in the 2nd quarter worth $26,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora in the second quarter worth about $30,000. Concord Wealth Partners purchased a new stake in shares of Cencora in the third quarter worth about $30,000. SYSTM Wealth Solutions LLC bought a new position in Cencora during the second quarter valued at approximately $36,000. Finally, Ashton Thomas Securities LLC bought a new position in Cencora during the third quarter valued at approximately $41,000. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.